[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2009028655A1 - Composé hétérocyclique et son utilisation - Google Patents

Composé hétérocyclique et son utilisation Download PDF

Info

Publication number
WO2009028655A1
WO2009028655A1 PCT/JP2008/065519 JP2008065519W WO2009028655A1 WO 2009028655 A1 WO2009028655 A1 WO 2009028655A1 JP 2008065519 W JP2008065519 W JP 2008065519W WO 2009028655 A1 WO2009028655 A1 WO 2009028655A1
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic compound
formula
disclosed
salt
symbols
Prior art date
Application number
PCT/JP2008/065519
Other languages
English (en)
Japanese (ja)
Inventor
Naoki Tomita
Takashi Imada
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of WO2009028655A1 publication Critical patent/WO2009028655A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un composé hétérocyclique ayant une forte activité inhibitrice de Raf. De façon spécifique, l'invention porte sur un composé représenté par la formule (I) ci-après ou sur un sel de celui-ci. (I) (Dans la formule, les symboles sont tels que définis dans la description).
PCT/JP2008/065519 2007-08-30 2008-08-29 Composé hétérocyclique et son utilisation WO2009028655A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-223951 2007-08-30
JP2007223951 2007-08-30

Publications (1)

Publication Number Publication Date
WO2009028655A1 true WO2009028655A1 (fr) 2009-03-05

Family

ID=40387366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065519 WO2009028655A1 (fr) 2007-08-30 2008-08-29 Composé hétérocyclique et son utilisation

Country Status (1)

Country Link
WO (1) WO2009028655A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143258B2 (en) 2008-12-02 2012-03-27 Takeda Pharmaceutical Company Limited Benzothiazole compounds useful for Raf inhibition
US8304557B2 (en) 2007-06-05 2012-11-06 Takeda Pharmaceutical Company Limited Fused heterocycle derivatives and use thereof
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2011115725A3 (fr) * 2010-03-16 2012-12-27 Dana-Farber Cancer Institute, Inc. Composés d'indazole et leurs utilisations
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10144730B2 (en) 2011-11-17 2018-12-04 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10906889B2 (en) 2013-10-18 2021-02-02 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US11040957B2 (en) 2013-10-18 2021-06-22 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN114805120A (zh) * 2022-05-23 2022-07-29 江苏瑞达环保科技有限公司 一种间氰甲基苯甲酸甲酯的合成工艺
US11826365B2 (en) 2009-12-29 2023-11-28 Dana-Farber Cancer Institute, Inc. Type II raf kinase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082272A1 (fr) * 2002-03-29 2003-10-09 Chiron Corporation Benzazoles substitues et leur utilisation en tant qu'inhibiteurs de la kinase raf
WO2005037273A1 (fr) * 2003-10-16 2005-04-28 Chiron Corporation Benzazoles substitues et leur utilisation en tant qu'inhibiteurs de la raf kinase
WO2006105865A1 (fr) * 2005-04-04 2006-10-12 Merck Patent Gmbh Derives d'acide quadratique d'indazole servant d'inhibiteurs de chk1, chk2 et sgk

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082272A1 (fr) * 2002-03-29 2003-10-09 Chiron Corporation Benzazoles substitues et leur utilisation en tant qu'inhibiteurs de la kinase raf
WO2005037273A1 (fr) * 2003-10-16 2005-04-28 Chiron Corporation Benzazoles substitues et leur utilisation en tant qu'inhibiteurs de la raf kinase
WO2006105865A1 (fr) * 2005-04-04 2006-10-12 Merck Patent Gmbh Derives d'acide quadratique d'indazole servant d'inhibiteurs de chk1, chk2 et sgk

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304557B2 (en) 2007-06-05 2012-11-06 Takeda Pharmaceutical Company Limited Fused heterocycle derivatives and use thereof
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8143258B2 (en) 2008-12-02 2012-03-27 Takeda Pharmaceutical Company Limited Benzothiazole compounds useful for Raf inhibition
US8497274B2 (en) 2008-12-02 2013-07-30 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US11826365B2 (en) 2009-12-29 2023-11-28 Dana-Farber Cancer Institute, Inc. Type II raf kinase inhibitors
WO2011115725A3 (fr) * 2010-03-16 2012-12-27 Dana-Farber Cancer Institute, Inc. Composés d'indazole et leurs utilisations
CN103080093A (zh) * 2010-03-16 2013-05-01 达纳－法伯癌症研究所公司 吲唑化合物及其应用
JP2013522292A (ja) * 2010-03-16 2013-06-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド インダゾール化合物およびそれらの使用
US8987275B2 (en) 2010-03-16 2015-03-24 Dana-Farber Cancer Institute, Inc. Indazole compounds and their uses
US10144730B2 (en) 2011-11-17 2018-12-04 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US10981903B2 (en) 2011-11-17 2021-04-20 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10787436B2 (en) 2012-10-18 2020-09-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US11040957B2 (en) 2013-10-18 2021-06-22 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US10906889B2 (en) 2013-10-18 2021-02-02 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US11325910B2 (en) 2015-03-27 2022-05-10 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US12098154B2 (en) 2015-03-27 2024-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN114805120A (zh) * 2022-05-23 2022-07-29 江苏瑞达环保科技有限公司 一种间氰甲基苯甲酸甲酯的合成工艺

Similar Documents

Publication Publication Date Title
WO2009028655A1 (fr) Composé hétérocyclique et son utilisation
WO2009025358A1 (fr) Composé hétérocyclique et son utilisation
WO2009028629A1 (fr) Composé hétérocyclique et son utilisation
WO2009048101A1 (fr) Composé amide
WO2008130021A3 (fr) Composé hydrazide hétérocyclique, et son utilisation comme pesticide
WO2009030469A8 (fr) Nouveaux fongicides
EP1953145A4 (fr) Compose heterocyclique presentant une activite inhibitrice de la 11- -hydroxysteroide deshydrogenase de type i
MY150989A (en) Benzothiazole compounds useful for raf inhibition
WO2009049716A8 (fr) Nouveaux fongicides
WO2009051244A1 (fr) Composé hétérocyclique
WO2009077443A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2008110355A8 (fr) Dérivés de quinoléine en tant que fongicides
WO2008123469A1 (fr) Composé amide à six chaînons et son utilisation
WO2009019015A8 (fr) Nouveaux herbicides
WO2008120759A1 (fr) Composé d'urée et son utilisation
WO2009060835A1 (fr) Nouvelle petite molécule de liaison de l'ubiquitine
WO2009077500A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2009041705A3 (fr) Composé hétérocyclique à 5 chaînons
IL184120A0 (en) 3,4-dihydro-1h-isoquinoline-2-carboxylic acid 5-aminopyridin-2-yl-esters
MY158982A (en) Heterocyclic compound
EP1854793A4 (fr) NOUVEAU COMPOSÉ AMINOPYRIDINE AYANT UNE ACTIVITÉ D'INHIBITION DE LA Syk
WO2007136592A3 (fr) Compositions à base de quinolones substituées et leurs utilisations
GEP20105033B (en) Therapeutic agent for diabetes
WO2009024342A3 (fr) Nouveaux microbiocides
WO2009077471A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828262

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08828262

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP